Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the very first quarter of 2021.

The present opinion among 11 TipRanks analysts is for a modest Buy rating of shares in CVS Health, with an average price aim of eighty four dolars.

The analysts price targets range from a high of hundred one dolars to a low of $61.

In its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The retail or Long Term Care segment has offering of prescribed drugs as well as assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as similar services, which includes medical, pharmacy, dental, behavioural health, healthcare relief abilities. The Corporate segment involves in providing administrative services as well as management. The company was created by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.